Human Longevity, a San Francisco, CA-based longevity focused technology company, completed an upsized $39.8M in Series B funding.
The round was led by TVM Capital Healthcare with participation from new and existing investors, including Panacea Venture and Emerging Technology Partners.
The company intends to use the funds to invest in its artificial intelligence health risk and recommendation platform, new longevity focused technologies and services, and new expansion sites globally.
Human Longevity is advancing human longevity care to discover and harness the technological and biological interventions that amplify span of life, health, & high-performance. By continually adding and analyzing its client’s health data, the company is innovating treatment from a reactive practice to one that is proactive, preventative, and personalized.
As result of research, they have created a 100+ Longevity care membership program to identify early stages of the major age-related health diseases, with the goal to increase healthspan and extend lifespan through the company’s clinical care team and data platform.
The 100+ Longevity Care program leverages precision medicine health data, clinical care, targeted interventions and the program also focuses on reducing biological age. Key components include whole genome sequencing, whole-body and brain MRI, comprehensive cardiac evaluation, body composition analysis, advanced blood biomarkers, and wearables.
FinSMEs
22/08/2024